A need for new monoclonal blood grouping reagents (BGRs) is evidenced by the age and declining performance of cell lines used in the manufacture of many BGRs currently on the market.
Realizing this, Siwa scientists dedicated themselves to developing new monoclonal antibodies with improved performance characteristics.
Siwa’s new IgM monoclonal antibodies are expressed from state-of-the-art recombinant Chinese Hamster Ovary (CHO) cell lines and have been incorporated into new BGRs for tube testing. Siwa’s recombinant IgM monoclonal Anti-Fya and recombinant IgM monoclonal Anti-Fyb BGRs are now FDA licensed. Recombinant BGRs with other specificities are in our development pipeline.
Siwa Biotech is introducing new monoclonal IgM Anti-Fya and Anti-Fyb Blood Grouping Reagents (BGRs). Unlike ordinary monoclonal antibodies, Siwa’s Anti-Fya and Anti-Fyb are the first recombinant BGR’s licensed by the FDA. Recombinant BGRs for Kell, Cellano, Jka, Jkb, S, s as well as other specificities are in our development pipeline.
Recombinant monoclonal antibodies are already being widely used today in miracle cancer therapeutics. Siwa is the first company to apply this same technology to BGRs. Siwa scientists accomplished this by isolating antibody gene sequences and using genetic engineering technology to create antibodies with improved performance characteristics. This has allowed Siwa to develop unique one-step Duffy IgM BGRs that eliminate the need for AHG, incubations and washing steps, saving time for the technologist.
To produce these antibodies, Siwa scientists introduced these improved antibody genes into Chinese Hamster Ovary (CHO) cells. These recombinant CHO cells then express our proprietary monoclonal antibodies which are incorporated into Siwa’s unique BGRs. These recombinant CHO cells should ensure a long term, consistent and stable supply of our antibodies. We believe this approach to the rare BGR space where the average hybridoma or heterohybridoma cell line is over twenty years old, will be very productive.
Lea has more than 25 years of experience in the manufacture of monoclonal blood bank reagents as Director of Raw Material Manufacturing at Immucor and Manager of Monoclonal Reagents at Gamma Biologicals.
Maria has more than 20 years of experience in the medical device and biologics Industry. She has held the positions Director of Quality at Gamma Biologicals and Immucor, Site Quality Head at Novartis/Alcon and Vice President of Quality at Cytovance Biologics.
Mike has spent more than 35 years in the blood bank diagnostic Industry, beginning his career in sales with Ortho Diagnostics and then becoming involved in the startup of two blood bank companies, BCA and Immucor. He served a combined 25 years as Director, then Vice President of Sales at Immucor.
Carolyn has more than 30 years of experience in immunohematology, which includes serving as Vice President, Worldwide Field Quality and Technical Support at Immucor, Director of Education and IRL at the American Red Cross, and Technical Director of Transfusion Services and Donor Testing at a community blood center.
Carol has more than 30 years of experience in immunohematology, serving as an assistant blood bank supervisor in a large trauma center and then as a supervisor of a large hospital transfusion service. She was a sales representative for both Gamma Biologicals and Immucor, as well as a regional manager at Immucor.
Hailey has several years of experience in the healthcare industry, beginning her career as a pharmaceutical sales representative and then joining Immucor as a blood bank automation specialist with sales responsibility for the southeastern US territory.
In addition to the employees above, Siwa Biotech is comprised of a very experienced and highly qualified group of MD and PhD scientists dedicated to the development of new clones producing monoclonal blood typing reagents.
Siwa was founded in 2005 by Drs. William Canfield (Chairman and CEO) and Kevin Moore (President). Both are trained Hematologists/Oncologists and former faculty at the University of Oklahoma Health Sciences Center. Dr. Canfield left the University in 1998 to found Novazyme Pharmaceuticals; subsequently acquired by Genzyme in 2001. From 2005-2015 he was Chairman of Cytovance Biologics until it was acquired by Hepalink. From 1998 to 2013 Dr. Moore was an investigator at the Oklahoma Medical Research Foundation a private, non-profit research institute in Oklahoma City.